Increasing evidence suggests that in the setting of an acute ischemic stroke due to carotid disease, the opportunity for improvement is greater with earlier treatment. Carotid disease accounts for up to 20% of all ischemic strokes. A meta-analysis of the large carotid randomized trials revealed that carotid endarterectomy (CEA) has the greatest benefit if it is performed within 2 weeks of symptom onset. 1 The early risk of an ischemic stroke after an initial transient ischemic attack (TIA) or minor stroke is significant. Up to 20% of stroke patients have an antecedent TIA, and up to 40% of these TIAs occur within 1 week before the stroke. 2 Minor strokes precede strokes in a similar proportion of patients. 3 These data have prompted attention to the benefit of reducing recurrent carotid-related ischemic events if carotid revascularization is performed shortly after the ischemic symptom onset. 4 Since the initial report by Rothwell et al 1 in 2004 , an increasing body of knowledge has supported the notion that an urgent or expedited carotid intervention shortly after an acute ischemic event is safe in select patients within 2 weeks from symptom onset. [5] [6] [7] [8] As a result, carotid interventions shortly after an acute neurologic ischemic event are being performed more frequently in stroke centers to reduce the risk of recurrent stroke.
In patients with acute ischemic strokes, systemic or intravenous thrombolysis with recombinant tissue plasminogen activator (tPA) is employed to recanalize thrombosed intracranial vessels (such as the middle cerebral artery or its branches) in up to 4.5 hours, once intracranial bleeding and other exclusion criteria are ruled out. 9, 10 Expanding use of tPA by stroke centers through telestroke networks for the treatment of acute ischemic strokes, together with the increasing support for the safety of performing early carotid interventions, is likely to increase the number of patients who may benefit from carotid intervention after tPA. However, tPA has a 6% risk of intracerebral hemorrhage (ICH), 11 and there are scant data as to whether tPA followed by urgent or expedited CEA or carotid artery stenting (CAS) has an increased risk of complications, particularly ICH 12 and neck or access site hematomas. Furthermore, there are few data regarding selection of patients and timing and safety of urgent carotid interventions for acute strokes after tPA. 13 We aimed to determine the effect of tPA on complications after urgent CEA or CAS and hypothesized that there is no difference in hemorrhagic risks for an acute carotid intervention after tPA compared with patients who do not receive tPA.
METHODS
All carotid interventions (CEA and CAS) performed between January 2009 and January 2015 in a single tertiary referral center, consisting of a vascular/stroke neurology team with 24-hour telemedicine stroke availability, were reviewed retrospectively from a prospectively gathered database after obtaining Institutional Review Board approval. Informed consent was waived by our Institutional Review Board. Carotid interventions (CEA and CAS) performed during the same (index) hospitalization for an acute cerebral TIA or stroke were deemed urgent, as previously defined. 6, 14 These patients underwent CEA or CAS for ischemic symptoms during the same admission as their initial presenting acute neurologic event, that is, during the index hospitalization. The origins of their admission varied between the emergency department, an outside hospital through a regional transfer center, and our institution's stroke telemedicine program.
Although there was no uniform protocol for intervention during the study period, inclusion criteria for this study comprised all patients who underwent urgent CEA or CAS for >50% internal carotid stenosis with some amount of neurologic recovery and less than a third of infarct volume on computed tomography (CT) or magnetic resonance imaging (MRI) of the head. No absolute National Institutes of Health Stroke Scale (NIHSS) score was used as a cutoff, although major debilitated strokes were generally not intervened on. As previously described, our institution has a dedicated stroke/vascular neurology service, through which all patients undergo a stroke workup and follow a pre-established clinical pathway.
14 A dedicated stroke/vascular neurology team assesses all patients with acute neurologic symptoms on admission, in accordance with our comprehensive stroke centercertified guidelines. Moreover, select patients presenting within 4.5 hours of an ischemic cerebral event who are deemed by the stroke/vascular neurologist to have an acutely ischemic middle cerebral artery or branch artery event are administered intravenous tPA at a dose of 0.9 mg/kg. The initial 10% is given as a bolus during 1 minute, followed by an infusion of the remaining 90% dose during 60 minutes, with a maximum dose of 90 mg. Patients are excluded from receiving tPA if they present with a baseline NIHSS score >25 or are receiving oral anticoagulation therapy; age in itself was not an exclusion criterion in our institution, although American Heart Association guidelines suggest exclusion if the patient is older than 80 years. Other specific exclusion criteria for tPA administration are history of head trauma or prior stroke in the previous 3 months, symptoms suggesting subarachnoid hemorrhage, previous ICH, or head CT scan demonstrating multilobar infarction; a number of less common contraindications to thrombolysis can be found in Jauch et al. 15 All patients underwent preoperative carotid ultrasound and either CT angiography with or without CT brain perfusion or magnetic resonance angiography of the neck. Antiplatelet therapy is held for 24 hours after tPA, and after this, all patients were maximally medically managed with dual antiplatelet therapy (aspirin 81 or 325 mg and clopidogrel 75 mg) and high-dose statin therapy (such as simvastatin 80 mg) until the carotid intervention. There was no particular delay to definitive carotid therapy as mean time was 2.4 days for the entire cohort. For patients undergoing CEA, aspirin 81 mg was used postoperatively, and the select patients who had CAS were treated with aspirin 81 mg and clopidogrel 75 mg.
The severity of the neurologic event was recorded with the ABCD2 score for a TIA and with the NIHSS score for stroke. The ABCD2 score predicts the stroke risk during 2, 7, 30, and 90 days after a TIA. 5, 16 ABCD2 is calculated by summing up points for five independent factors: age >60 years, blood pressure (systolic $140 mm Hg or diastolic $90 mm Hg), clinical features of TIA (presence of unilateral weakness or speech impairment), duration of symptoms (10-59 minutes vs >60 minutes), and presence of diabetes mellitus (total score of 1-7). A low ABCD2 score, between 0 and 3, has a 7-day risk of stroke of 1.2%, whereas a high score of 6 or 7 has a 7-day risk of stroke of 11.7%. Of note, a recent report suggested that the utility of the ABCD2 score lies largely in predicting the severity of recurrent events after TIA; a high ABCD2 score was associated with a major recurrent stroke, and a low score was associated with high rates of recurrent TIAs. 17 For strokes, the NIHSS score is a clinical tool that can be assessed at the bedside, similar to the ABCD2 score for TIAs; it quantifies the severity of strokes as minor (1) (2) (3) (4) , moderate (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) , moderate to severe (16) (17) (18) (19) (20) , and severe (21-42; www.nihstrokescale.org). Patients with dense ischemic cerebral events, hemorrhagic conversion, or severe strokes with NIHSS score >26 were not offered urgent operative management.
Exclusion criteria for the study were all patients undergoing CEA or CAS during this period who were asymptomatic or symptomatic but had elective procedures, that is, not during the index hospitalization. This latter group underwent carotid intervention well over 15 days from symptom onset and during a different admission. The primary reason for the group of patients who had symptomatic carotid disease but had elective procedures was their presentation well after the ischemic event in a clinic or outpatient setting.
CEAs were performed by vascular surgeons using standard patch angioplasty closure after endarterectomy with routine intraoperative shunt use. For the 30 urgent CAS procedures, 13 were performed by vascular surgeons (43.4%), 10 by interventional cardiologists (33.3%), and 7 by interventional neuroradiologists (23.3%). General anesthesia was performed for all urgent CEA cases, whereas local anesthesia was used for all urgent CAS cases.
CEA was the preferred mode of carotid revascularization, but CAS was done in cases involving medically high-risk patients, such as chronic obstructive pulmonary disease with home oxygen dependence or severely depressed ejection fraction <20%, and judged by a vascular surgeon to have an unacceptable risk for CEA or high anatomic risk, such as previous surgery or neck irradiation. In such instances, CAS with either proximal protection (Mo.Ma proximal cerebral protection device [Medtronic, Santa Rosa, Calif]) or distal embolic protection was performed, depending on the interventionalist.
Postoperatively, as part of the stroke service clinical pathway, stroke-certified nurses closely monitored all patients, either in the postanesthesia recovery area or the neurointensive care unit. Neurologic examinations were performed by the dedicated stroke/vascular neurology service. Tight blood pressure control, with a goal of <150 mm Hg systolic, was of utmost importance in the postoperative period management of the patients undergoing acute carotid interventions to prevent cerebral hyperperfusion syndrome and hemorrhagic conversion of an ischemic stroke.
The primary end points of the study were to compare the effect of tPA on 30-day complications, including ICH or any bleeding, myocardial infarction (MI), stroke, or death. ICH was defined as any worsening change in the neurologic examination findings confirmed by hemorrhage using CT of the head or MRI of the brain. Any bleeding was defined as a neck hematoma for CEAs, gastrointestinal bleeding, or groin/access hematoma for CAS procedures. MI was defined by typical angina chest pain with elevated serum biomarker troponin I or electrocardiographic changes. Stroke was defined as a new cerebral neurologic deficit persistent for 24 hours. To determine significance between groups, Wilcoxon rank sum test was used for numeric variables and c 2 or Fisher exact test for categorical variables.
RESULTS
From January 2009 to January 2015, 762 patients underwent carotid interventions (CEA, n ¼ 440; CAS, n ¼ 322) at our tertiary referral center. Of these, 165 patients (21.6%) underwent an urgent carotid intervention for an acute neurologic symptom, including acute cerebral TIAs or strokes, and are the focus of this analysis (Fig 1) . Stroke was the presenting symptom in 130 patients and TIA in 35 patients. For these acute ischemic events, the urgent carotid interventions were CEA (n ¼ 135) and CAS (n ¼ 30) during the index hospitalization. Of these, 19% had tPA (n ¼ 31 [CEA, n ¼ 25; CAS, n ¼ 6]) and the rest (81%, n ¼ 134 [CEA, n ¼ 110; CAS, n ¼ 24]) did not receive tPA because they were outside the tPA time window of 4.5 hours. Demographics and preoperative characteristics were similar between the two groups (Table I) . Most strokes were minor or moderate, with a mean NIHSS score of 6.6 (range, 0-19) in the tPA group and 6.1 (range, 0-26) in the no-tPA group (Table II) .
The mean time from admission with an acute ischemic event to carotid intervention (CEA or CAS) was 2.4 days (0-15); for the tPA group, it was 2.2 days (0-7) compared with 2.6 days (0-15) for the no-tPA group (P ¼ .45; Fig 2) . In the tPA cohort, more than half of the patients (17 of 31) underwent revascularization within 72 hours (CEA ¼ 13; CAS ¼ 4), and no worse outcomes were noted in these patients compared with those who underwent revascularization after 72 hours. With a total of 31 thrombolysis patients, there were two complications in the <72 hours group (one ICH, one death) and one patient who sustained two complications (hematoma and subsequent death at 30 days) in the >72 hours group. Other perioperative characteristics of each group are summarized in Table II .
The 30-day stroke, death, and MI rates were 9.7% (3 of 31) for the tPA group compared with 4.5% (6 of 134) for the no-tPA group (P ¼ .38). The overall (stroke, death, MI, and any bleeding) 30-day complication rate was not different between the tPA group (3 of 31) and the notPA cohort (8 of 134; P ¼ .43). In the tPA group, there were one ICH, one neck hematoma/death, and an additional death; in the no-tPA group, there were one ICH, two neck hematomas, one stroke, two MIs, one ICH/ death, and one additional death (Table III) . In the tPA group, one patient underwent CAS for an occluded internal carotid artery and a high-moderate stroke with an NIHSS score of 15, who the stroke team thought had potentially salvageable brain tissue, which progressed to 21 immediately after the procedure. A few hours after stent placement, the patient had a hemorrhagic stroke conversion of his dense ischemic stroke. A second patient underwent CEA for a moderate stroke with an NIHSS score of 10. He was readmitted 30 days after the procedure secondary to a pulmonary embolus and hypotension, resulting in death. A third patient underwent CEA for a minor stroke with an NIHSS score of 1 and had two complications; on postoperative day 0, he developed a neck hematoma requiring a return to the operating room for hematoma evacuation, and although he was discharged home, he had an unknown cause of death within 30 days. In the no-tPA group, one patient (patient 2, Table III) had a CEA for a moderate stroke with an NIHSS score of 11 and had a hemorrhagic stroke conversion postoperatively. A second patient (patient 8) sustained an ICH shortly after undergoing CAS for a severe stroke with an NIHSS score of 25. This patient's hemorrhagic stroke conversion led to his death on postoperative day 9. Two additional patients had a CEA for a mild stroke and developed a neck hematoma, which required evacuation postoperatively. Another patient had a CEA for an acute severe stroke with an NIHSS score of 24 and was readmitted with acute-on-chronic mesenteric ischemia, which proved fatal. Two MIs occurred in this cohort, one after CEA and another after CAS. The sole postprocedure ischemic stroke was in a patient treated with CAS for a moderate stroke (admit NIHSS score of 11); this patient was readmitted within the 30 days after the procedure for a recurrent ischemic stroke.
There were no differences in individual complications between the two groups. Postprocedure MI was none for tPA and 2 of 134 for no tPA (P ¼ 1.0); postprocedure stroke was none for tPA and 1 for no tPA (P ¼ 1.0); death was 2 of 31 in the tPA group compared with 2 of 134 in the no-tPA group (P ¼ .16). Any type of bleeding complications after CEA or CAS in patients who did or did not receive tPA was also not different. Bleeding complications alone (ICH and neck hematomas) were not different between the tPA group (2 of 31; 1 ICH, 1 neck hematoma) and the no-tPA group (4 of 134; 2 ICHs, 2 neck hematomas; P ¼ .32).
DISCUSSION
We compared the effect of tPA on 30-day complications, including ICH, any bleeding, stroke, death, and MI, and describe what is often missing in other series, timing of CEA or CAS after tPA and presenting stroke severity (NIHSS score). We demonstrate that tPA followed by urgent CEA or CAS is not associated with an increased risk of complications, including bleeding complications, in select patients who present with acute neurologic symptoms. Most of the patients in our cohort had CEA compared with CAS for the treatment of acute carotidrelated cerebral ischemia. We did not notice an increased bleeding risk, and in particular the dreaded complication of ICH, in patients with minor or moderate strokes whose carotid intervention was performed after receiving tPA. In this highly selected subgroup of patients, tPA utilization rate followed by CEA or CAS was 19%, much higher than the reported incidence in the literature of 4% to 7%, 13, 18, 19 because of the existing telestroke network in our health system. Moreover, by being a tertiary referral center with a comprehensive stroke center status that uses a telestroke network, the overall volume of stroke patients and subsequently carotid-related stroke patients has increased.
14 Selection of patients is important, as most patients in our series had a minor or moderate ischemic stroke. In fact, the three patients who sustained an ICH of the 165 patients in our series presented with moderate to high NIHSS scores. These patients had (1) a moderate stroke (NIHSS score of 11) in a patient after CAS who received tPA, (2) a high-moderate stroke (NIHSS score of 15) in a patient after CEA who did not receive tPA, and (3) a severe stroke (NIHSS score of 25) in a patient after CAS who did not receive tPA. Although there were several other patients with high NIHSS scores who did not sustain an ICH (Fig 3) , it could be argued that these patients with fairly high NIHSS scores should not have been offered an urgent carotid revascularization, although other patients with similar NIHSS scores did not have such complications. These observations highlight that tPA administration may not be an important factor in predicting a postoperative complication.
Our data also suggest that reserving urgent carotid revascularization for those patients with minor or moderate strokes (NIHSS score <10) is prudent. There were no ICHs in either group of patients with NIHSS score of <10 and only one death in the thrombolysis group of patients with NIHSS score of <10. In the tPA group, there were 8 patients with an NIHSS score >10, and this was the sole ICH case in this group; in the no-tPA group, there were 21 patients with NIHSS score >10, and 2 ICHs and 1 stroke occurred among this subgroup. Hence, although we remain aggressive at early/urgent carotid revascularization after an acute neurologic ischemic symptom, we have been less aggressive at offering urgent carotid revascularization to patients with severe strokes (NIHSS score >21) and offer it on a case-by-case basis in moderate to severe strokes (NIHSS score of [16] [17] [18] [19] [20] , favoring intervention if the patient has made a good neurologic recovery and there is no intracranial bleed. For patients with minor (NIHSS score 1-4) or moderate (NIHSS score 5-15) strokes, our evolving institutional practice is to offer urgent carotid revascularization within 72 hours if the patient has made a good neurologic recovery and there is no intracranial bleed on head imaging by CT or MRI.
One other important facet in the evaluation of patients with an acute stroke presenting with high NIHSS scores is whether there is salvageable brain tissue to revascularize. In these instances, we have found use of CT brain perfusion scans, which are interpreted by stroke neurologists or neuroradiologists, to be valuable. CT brain perfusion scan can determine whether salvageable brain tissue, penumbra, is present and differentiates this from other strokes that are infarcted and are irrevocable regardless of therapy, known as the infarct core. 16 Fig 4 illustrates these two different CT perfusion scans. In interpreting the four panels of a CT perfusion scan, cerebral blood volume (CBV) is a surrogate for core infarct. If CBV is normal (same on both hemispheres), collaterals are bringing flow to the area; when it is present with decreased cerebral blood flow (CBF), this mismatched defect represents an ischemic penumbra. If CBV is decreased alongside CBF, this matched defect signifies a core infarct. Fig 4, A is of a patient who has sustained a large left posterior middle cerebral artery stroke, and there is a matched defect with decreased CBF and poor CBV, typical of a core infarct on CT perfusion. In patients presenting with high NIHSS scores, there is little utility in performing an urgent carotid intervention as there is little brain tissue to recover. Contrary to this, Fig 4, B demonstrates an ischemic penumbra in the left hemisphere after a large left middle cerebral artery stroke; the CBF is decreased and the CBV is normal (same on both hemispheres). In these scenarios, an urgent carotid intervention may be warranted. We have found CT brain perfusion scans useful particularly in patients with an acute carotid occlusion who have made some recovery and in patients with a presenting high-moderate or severe NIHSS score (usually >16). However, this is our anecdotal institutional data, and future studies will need to address the utility of this technology in identifying potentially salvageable brain tissue in cases of acutely symptomatic carotid disease. Our evolving practice is to offer an urgent carotid intervention if the patient has no demonstrable blood on CT or MRI of the head and has made at least a fair neurologic recovery and there is indeed a large penumbra.
Concern has been raised about the use of tPA and urgent carotid interventions. In a small institutional series, tPA followed by CEA resulted in 2 of 11 patients developing ICH compared with 1 of 131 patients not treated with tPA. 20 However, this was not supported by a larger registry data set from Sweden, Denmark, and Finland. 19 Although this multinational registry was not able to report TIA or stroke severity or time from symptom onset to carotid intervention for the no-tPA group, 202 patients who had tPA followed by CEA had no increased stroke or death compared with 5526 patients with symptomatic carotid disease not treated with tPA. No data were given on bleeding complications in this registry, and it demonstrated a low tPA utilization rate of 4%.
The growing number of telestroke networks will likely increase the currently low tPA utilization rates of 3% to 5% for all acute ischemic strokes in the United States. 15, 21 As tPA use remains the only Food and Drug Administration-approved treatment for an acute ischemic stroke within 3 hours of symptom onset, community hospitals with limited experience using tPA are likely to increase intravenous tPA utilization through telestroke networks. 22 The tPA time window is expanded to 4.5 hours in comprehensive stroke centers to increase the number of patients who can be treated. A system wherein there is a close working relationship between vascular surgery and stroke/vascular neurology is key to achieving success in a population of such high-risk acute patients. 14 In our center, a vascular neurologist assesses all patients with ischemic strokes who may require urgent CEA or CAS on admission. This collaboration also aids in managing the patient perioperatively in a stroke intensive care unit as it is imperative to avoid postprocedure hypertension by tight blood pressure control; this helps avoid the feared complication of cerebral hyperperfusion syndrome and risk for development of ICH.
A meta-analysis of the large carotid randomized trials revealed the greatest benefit of an early CEA to be within 2 weeks after acute symptom onset. 1 In this meta-analysis, benefit from CEA was greatest in men, with age >75 years, and in patients who underwent CEA within 2 weeks after the last ischemic event. The number needed to treat to prevent an ipsilateral stroke in 5 years was 5 for patients who were randomized to CEA within 2 weeks compared with 125 for patients randomized after 12 weeks. 1 These types of analyses based on large randomized data have led to calls for urgent or expedited CEA after a TIA or stroke. 4 However, data on the timing of CEA after tPA are more scant, as it has been reported in only some series. 13, 19, [23] [24] [25] In these series, the range of median times reported from tPA to CEA or CAS was 7 to 12 days. We found it safe to perform an urgent CEA or CAS even within 3 days. One caveat raised in regard to CEA early after an initial ischemic event, however, lies in the downstream effects of systemic tPA on the coagulation cascade. Despite a short half-life of approximately 4 minutes, caution has been raised about the remaining effects of systemic tPA lasting up to 72 hours on the coagulation system and increased permeability of the blood-brain barrier, both of which may predispose a patient to development of ICH. 12 We did not see any differences among the 31 patients in the tPA cohort who underwent an urgent CEA or CAS within 72 hours (one ICH, one death) compared with >72 hours (one patient who sustained two complications, a hematoma and subsequent death at 30 days) after tPA administration. Recently, data from the Swedish Vascular Registry (Swedvasc) reported increased mortality and stroke rates if CEA was undertaken within 2 days compared with day 3 and beyond. 26 Although our cohort of patients is smaller than in this registry report, we did not see an effect on timing and significant increased rates of bleeding or other Computed tomography (CT) brain perfusion scans demonstrating core infarcts and an ischemic penumbra. A, Matched defect on CT perfusion scan demonstrating a large core infarct in the left posterior middle cerebral artery territory. There is no need to do an urgent CEA or CAS. This CT perfusion scan shows a matched defect with decreased cerebral blood flow (CBF) and poor cerebral blood volume (CBV), typical of core infarct. Top left, CBF is decreased (purple area). Top right, CBV is also decreased (blue/purple area). Bottom left, Mean transit time is elevated (red/yellow area). Bottom right, Time to peak is also elevated (red/yellow area). Right image, Magnetic resonance imaging (MRI)/diffusion-weighted imaging demonstrates an infarcted tissue corresponding to the territory with matched defect on CT perfusion. B, An ischemic penumbra is identified in the left hemisphere. Left image, CT perfusion map shows a left middle cerebral artery stroke, but there is a mismatch between CBF and CBV. Top left, CBF is decreased (purple area). Top right, CBV is normal or the same on both hemispheres. Bottom left, Mean transit time is elevated (red/yellow area). Bottom right, Time to peak is elevated (red/yellow area). Right image, MRI/diffusionweighted imagingdsmall watershed infarcts in the left middle cerebral artery territory corresponding to the territory on the CT perfusion scan. complication within the tPA cohorts compared with the notPA group of patients who underwent revascularization within 72 hours.
The majority of the patients in our series underwent CEA over CAS for urgent carotid treatment because of the known lower periprocedural stroke risk. Although one large randomized trial demonstrated no differences in the cumulative end points (stroke, death, and MI), 27 a second large trial reported decreased combined periprocedural complications with CEA compared with CAS. 28 Moreover, both trials demonstrated lower rates of periprocedural stroke risk with CEA compared with CAS. Consequently, CEA remains the mainstay of treatment for symptomatic carotid disease. CAS is reserved for medically or anatomically high-risk patients who are deemed not able to tolerate a CEA. When performing CAS in the acutely symptomatic patient, we favor CAS with proximal protection to help minimize embolization 29 from the vulnerable carotid plaques, which are often found in this group of patients. Although concern could be raised that such patients may not tolerate transient (2-4 minutes) carotid flow reversal, we did not notice this to be a significant problem in the patients treated in this manner.
This study has certain limitations; it is a retrospective review of a prospectively collected database. Patients who have had tPA followed by CEA or CAS are a highly selected subgroup of patients. Despite an analysis encompassing a 6-year review of 165 urgent carotid interventions and a tPA rate of 19%, which is higher than that previously reported for such series, the sample size of patients receiving tPA and CEA or CAS was 31. Hence, further studies are needed to confirm whether the low stroke and bleeding rates we observed will be replicated in larger sample sizes. Although there were no statistical differences in death rates between the two groups, the tPA group had a 6.5% (2 of 31) mortality compared with 1.5% (2 of 134) mortality in the no-tPA group (P ¼ .16). Although the rates of ICH, stroke, and MI were similar between these two groups, the death rate is large enough to suggest a likely type II error, and future studies with larger numbers may shed more light on whether there is an increased risk of mortality with tPA administration. Sample size can be increased by studying registry data sets; indeed, a recent multinational registry reported safety of CEA after tPA for 202 patients 19 ; however, it lacked certain detailed data, such as stroke severity and information on any bleeding complications.
CONCLUSIONS
This study supports the notion that urgent or expedited CEA or CAS can be safely undertaken in minor or moderate strokes (NIHSS score <10) with low complication rates, including ICH and neck or access site hematomas. Although our data suggest that reserving urgent carotid revascularization for those patients with minor or moderate strokes (NIHSS score <10) is prudent, it will need to be further validated in future studies. There were no ICHs in either group of patients with NIHSS scores of <10 and only one death in each group of patients with NIHSS scores of <10. Since the current trend for stroke treatment is to intervene early, our data support the practice to not deny a patient an urgent carotid intervention simply because the patient received tPA, particularly in patients with minor or moderate strokes who have made a good neurologic recovery. The decision to intervene urgently on a carotid lesion after tPA should be based largely on the stroke severity, neurologic recovery, and absence of blood on CT or MRI of the head. The role of demonstration of an ischemic penumbra by CT brain perfusion should be addressed by future studies. Thrombolysis in itself does not appear to be a contraindication to performing an urgent CEA or CAS for minor or moderate strokes. Have you read the TransAtlantic Debate, which was published in the Journal of Vascular Surgery and the European Journal of Vascular Surgery, in regard to whether carotid artery stenting (CAS) or carotid endarterectomy (CEA) is more appropriate in patients with neurologic deficits in the acute setting? It just so happens that I was assigned to represent North America, and I was assigned the part that CAS is preferable over CEA in these patients. During my research in this regard, I encountered several studies that showed that CAS was not inferior to CEA in patients with neurologic deficits during the acute stage; however, all of these series, except one, were relatively small. With this in mind, I am wondering if you took this into consideration in your study, and if you separated your patients between those who underwent CAS vs CEA.
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Second, did you consider the neurologic status of these patients prior to intervention? Since, as you know, most of us would not offer intervention to patients with severe neurologic deficits.
I would appreciate your comments regarding these two questions.
Thank you.
Dr Nicolas Zea. In regard to the first question, we did not analyze the individual outcomes between CAS or CEA, but this is definitely a good point that we can analyze in the future. Of note, we did favor endarterectomy as our initial procedure of choice and only reserved CAS for high-risk patients.
In regard to mixing patients between minor and moderate or severe strokes, we did look at the cohort as a whole. We then performed a subanalysis of the different degrees of stroke severity in regard to outcomes and showed that patients with minor to moderate stroke, with a National Institutes of Health Stroke Scale (NIHSS) score <10, didn't have the dreaded complications of death or intracerebral hemorrhage. Of the three patients that had intracerebral hemorrhages, one of those actually had a NIHSS score of 25. From this, one can say that perhaps we were too aggressive in our patient selection and hopefully this new data shows how it will be a lot safer to perform urgent carotid interventions in minor to moderate stroke patients.
Dr Wilhelm Sandmann (Duisburg, Germany). As I am in vascular surgery now 45 years, I would remind you that Paolo Fiorani in Rome more than 30 years ago insisted that you could operate on a patient with acute stroke and acute occlusion of the internal carotid artery. At the same time, the Americans, they are running a joint study, probably the elder ones remember, William Blaisdell was involved, and the result of the study was acute surgery is useless and it is very dangerous because the patient will end up with intracranial bleeding. I would like to know an explanation probably from you, because I think you have studied the literature, what has changed really in the management that today, even after administering tissue plasminogen activator (tPA) and urgent carotid artery surgery, the patient does not develop intracranial hemorrhage, what is the explanation for these changes?
Dr Zea. What changed in the last couple of years is the knowledge of absolute risk reduction in 5-year stroke risk if a carotid intervention is performed within the first 2 weeks from symptom onset; this is known thanks to the pivotal review by Dr Rathenborg et al.
In regard to the utilization of tPA, the utilization rate continues to increase and will continue to increase in the years to come, leading to a higher number of symptomatic carotid stenosis post-thrombolysis. Secondary to this we found the need to ask the question if complication rates were any different between lysis patients vs no lysis patients after a carotid intervention. This is the hypothesis of our project and the one that we answered in our presentation and submitted manuscript.
Dr Sandmann. If I may make a suggestion, you should describe in your paper which is published a little bit more clearer what are the selection criteria in which you can do this kind of treatment and in which patients it is dangerous.
Dr Anthony Comerota (Toledo, Ohio). Very professionally presented, thank you. Your data reflect ours, although ours is a much smaller series than yours. As you know, systemic tPA is diminishing in preference to catheter-based interventions, which have now been shown to be superior. Our neurointerventionalists have observed the safety of the CEA in patients successfully treated with catheter-directed thrombolysis. They now suggest that we do CEA, in preference to carotid angioplasty and stenting, to treat residual carotid bifurcation disease following catheter-directed tPA to avoid combined platelet inhibition after the procedure. As we now know, combined platelet inhibition is associated with the higher risk of bleed. Could you give us your opinion regarding treatment of carotid bifurcation disease following catheter-directed thrombolysis?
Dr Zea. It's an excellent question and an important observation. Thrombolysis carries a 6% risk of hemorrhagic stroke conversion; therefore, anything to minimize the risk of postoperative bleeding is of utmost importance. Postoperative care with monoantiplatelet therapy (as with CEA) would theoretically carry a lower risk of bleeding compared with dual antiplatelet therapy (as with CAS). We do preferentially perform CEA in the urgent setting after lysis, only utilizing CAS in high-risk patients not fit for an open operation.
Dr Hernan Bazan (New Orleans, La). Very quickly to answer a couple of the questions that were raised. In regard to Dr Aburahma's question, in general we favor CEA, and this is clearly described in the manuscript, particularly due to the lower risk of stroke with CEA compared with CAS. The patients in our series that underwent CAS were not candidates for CEA due to severe chronic obstructive pulmonary disease, ischemic cardiomyopathy (such as ejection fraction <20%). And, when CAS was done, it was done preferably with proximal protection.
The other question about hemorrhagic conversion is critically important in this patient population that presents with an acute carotid-related stroke. Periprocedurally, we follow very tight blood pressure control to prevent the dreaded complication of cerebral hyperperfusion, which is also described in our submitted manuscript. Last, acute carotid occlusions are treated within hours of presentation.
